Daily Newsletter

10 June 2024

Daily Newsletter

10 June 2024

Stimvia reports positive results from PD treatment trial

The study focused on the use of the company’s non-invasive URIS device.

Archana Rani June 10 2024

Medical technology company Stimvia has announced initial positive results from its pilot study for a new add-on treatment for patients with Parkinson's disease (PD).

The study focused on the use of the company's non-invasive URIS neuromodulation device, which has shown potential to improve the quality of life for PD patients.

It involved 12 PD patients who met the inclusion criteria. They underwent daily 30-minute sessions of stimulation using the URIS device for six weeks.

Following this treatment phase, the patients entered a six-week observation period without stimulation to evaluate the lasting effects of the therapy.

Stimvia is set to release the complete data from the pilot study in the coming months.

The URIS technology is designed to operate on the principle of electrical transcutaneous nerve modulation (eTNM).

Stimvia CEO Lukas Doskocil said: “Since the URIS technology demonstrated a positive impact in treating Parkinson's disease, Stimvia plans substantial investment in further clinical trials to validate the method's efficacy and safety.

“We believe our technology can introduce new, additive treatment modalities for millions of patients who currently have no other options, potentially offering a positive disease-modifying impact on those with Parkinson's disease.”

Stimvia's URIS technology has already demonstrated efficacy in treating overactive bladder, a condition affecting an estimated 40 million people in the US alone.

Ostrava University Medical Faculty Science and Research vice-dean and study lead professor David Skoloudik said: “We are pleased to share preliminary findings indicating promising results. Patients have reported improvements in both the number of Parkinson's disease symptoms and their overall quality of life.

“Furthermore, we have observed a notable reduction in resting tremor. While the precise data are still under rigorous evaluation, we remain cautiously optimistic about the potential implications of these outcomes.”

Regulated mHealth Apps Overview

GlobalData's latest thematic intelligence report discusses the mHealth software technologies and the emerging trends that will impact the use of these apps in the healthcare industry in the coming years. The report also covers value chain insights, key players, and sector scorecard analysis. While there are several categories of mHealth apps, our report will focus on medical apps, which are regulated and generally need a prescription or corresponding device to use.

Regulated mHealth Apps Overview

GlobalData's latest thematic intelligence report discusses the mHealth software technologies and the emerging trends that will impact the use of these apps in the healthcare industry in the coming years. The report also covers value chain insights, key players, and sector scorecard analysis. While there are several categories of mHealth apps, our report will focus on medical apps, which are regulated and generally need a prescription or corresponding device to use.

Regulated mHealth Apps Overview

GlobalData's latest thematic intelligence report discusses the mHealth software technologies and the emerging trends that will impact the use of these apps in the healthcare industry in the coming years. The report also covers value chain insights, key players, and sector scorecard analysis. While there are several categories of mHealth apps, our report will focus on medical apps, which are regulated and generally need a prescription or corresponding device to use.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close